Introduction {#S1}
============

Severe combined immunodeficiency disease (SCID) is considered a medical emergency since it is the most severe form of primary immunodeficiency disorders (PID). SCID is a genetically heterogeneous group of over 20 monogenic inherited inborn errors of the immune system characterized by lack of T lymphocytes development from the thymus, in addition to deficiencies of B cells, NK cells, or both in some forms. Impaired cellular and humoral immunity makes affected infants susceptible to bacterial, viral, fungal, and opportunistic infections and results in death within the first 2 years of life. Infants with SCID can be rescued with hematopoietic stem cell transplantation (HSCT) and for some forms by using gene therapy or enzyme replacement therapy ([@B1]--[@B4]).

Severe combined immunodeficiency disease meets newborn screening (NBS) disease criteria, as affected infants are asymptomatic at birth, disease is lethal without treatment, and outcome significantly improve if early management is offered ([@B5]--[@B7]). HSCT is the most effective curative treatment and the outcome is influenced by age at diagnosis and clinical status of patients at presentation ([@B8], [@B9]). High (95%) overall survival was observed among infants undergoing transplantation in the first month of life in comparison to those treated after 3 months of age (70%) ([@B3]--[@B7]).

Excision and splicing of the DNA encoding the T-cell antigen receptor genes are required during normal T cell development and differentiation to produce T cells with diverse antigen specificities. During T cell receptor rearrangement, deleted DNA fragments circulate without further replication in dividing cells. T-cell receptor excision circle (TRECs) is an excellent marker of recently formed T cells ([@B10]). In 2005, Chan and Puck first described the TREC assay as an excellent tool for population-based NBS for SCID ([@B11]). TREC copy number can be determined from Guthrie card dried blood spots (DBSs) using real-time quantitative polymerase chain reaction (RT-qPCR) ([@B12]).

In 2008, the TREC assay-based NBS for SCID was first implemented in WI, USA ([@B13]). Universal SCID NBS was then recommended in 2010 by the US Advisory Committee on Heritable Disorders in Newborns and Children. Currently, most states provide NBS for SCID using the TREC assay and several pilot studies are ongoing in Europe and Asia ([@B14]--[@B18]). The results of screening three million newborns showed a SCID frequency of 1/58,000 children and a higher overall frequency (1/7,300) of significant forms of T cell lymphopenia ([@B19]). SCID incidence is expected to be higher in populations with high rates of consanguinity ([@B20]--[@B22]).

Depending on how you set the cut limit, TREC assay can also identify non-SCID immunodeficiencies with profound decrease in circulating naïve T-cells including: 22q11 deletion syndrome, trisomy21, CHARGE syndrome, Kabuki syndrome, Ataxia telangiectasia, *DOCK8-*related autosomal recessive hyper IgE syndrome, Cartilage hair hypoplasia, Nijmegen breakage syndrome, Schimke immune-osseous dysplasia, preterm infants, and idiopathic lymphopenia in addition to other disorders such as vascular leakage, chylous effusions, congenital leukemia, and congenital heart diseases, which cause T cell loss ([@B19], [@B23]--[@B26]).

Most causes of monogenic SCID have an autosomal recessive mode of inheritance and hence they are expected to be more common in areas with high rates of consanguineous marriages ([@B21], [@B27], [@B28]). Consanguineous marriages are common in Saudi Arabia with an overall incidence of 60% ([@B29]). In this study, we have conducted a pilot TREC-based NBS to assess the incidence of SCID and other combined immunodeficiencies associated with low TREC among the Saudi population and examine the clinical utility of a targeted next generation sequencing (NGS) PID gene panel as a confirmatory diagnostic tool for mutation screening of Guthrie card DBS with low TREC count.

Materials and Methods {#S2}
=====================

Ethical Approval {#S2-1}
----------------

All research involving Guthrie card (DBS) samples was approved by the institutional review board at King Faisal Specialist Hospital & Research Center (KFSHRC), RAC:2130-027. The ethical board waived informed consent since samples were anonymized. This work was supported by the Kingdom of Saudi Arabia National Science, Technology and Innovation Plan's Strategic Technologies Grant KACST: 13-BIO 755-20 under the King Abdulaziz City for Science and Technology (Riyadh, Kingdom of Saudi Arabia).

Screened Samples {#S2-2}
----------------

In Saudi Arabia, NBS officially began in 2005. Currently, there are three NBS programs that provide screening for about 50% of all (570,000) newborns ([@B30]). The Newborn Screening & Biochemical Genetics Laboratory at King Faisal Specialist Hospital and Research Centre (KFSHRC) receives samples from all provinces of Saudi Arabia and screens about 80--90,000 live births every year. DBS specimens were obtained from Guthrie cards collected over a 12-month period (November 10, 2015--November 30, 2016). Within 1--3 days after completing the routine NBS tests, DBS samples were randomly selected with an average of 1,000 samples every month. Prior to anonymization, gestational age and birth weight data were collected. Large punches from selected DBSs were anonymized and coded to prevent any possibility of tracing the identity of the newborn behind the sample. The anonymized samples were then punched and processed for the TREC assay and potential additional second tier analyses.

TREC Assay {#S2-3}
----------

The Enlite™ Neonatal TREC assay is an FDA approved, high throughput (96 or 384 well) based assay (Perkin Elmer, Turku, Finland). The details of this assay had been described previously ([@B14], [@B18], [@B31]). Briefly, the assay utilizes 2-plex amplification of TREC and beta-actin (ACTB) in the same reaction for each specimen. It uses a combination of end-point polymerase chain reaction (PCR)-based deoxyribonucleic acid amplification and time-resolved fluorescence resonance energy transfer (TR-FRET)-based detection. Calibrator and control samples are used to calculate TREC and ACTB copies and for monitoring the assay performance. Unlike all other routine NBS assays, which use a standard 3.2 mm punch, for the Enlite assay uses a 1.5 mm DBS punch from each sample into a PCR-plate directly, which is then incubated with 10 µL elution buffer (5× Phire^®^ buffer mixed with elution diluent) followed by combined DNA amplification and hybridization, and signal measurement using the VICTOR Enlite fluorometer. And the EnLite™ workstation software was used to interpret test results based on two separate calibration curves, which use blanks and DBS calibrators A--C. The response, corrected counts, are fitted against the ArcSinh transformed concentrations (copies/μL) using the unweighted linear regression. The test quality control is based on three kit control results interpretations. The initial manufacturer provided cutoffs were as follows: TREC positive: ≥36/μL, TREC negative: ≥36 copies/μL, and Beta-actin (ACTB) copy of ≥56 copies/μL. The test result is valid when Beta-actin copy of ≥56 copies/μL. Since by study design, no clinical follow-up of screen positive cases was possible and to ensure the identification of all newborns with classical SCID and possibly other combined immunodeficiencies with low TREC, we elected to use the manufacturer recommended cutoff at 36 copies/μL. To test the validity of this cutoff limit, a previously collected Guthrie card samples from nine molecularly confirmed patients with atypical AK2 deficiency were utilized for assay validation and setting the cutoff limit. Triplicate TREC copy number analysis was run in each sample except one, which was run in singlicate. The mean and median TREC copy number was 13.3 and 13.5, respectively, while the range was 0--28 copies/μL.

DNA Extraction {#S2-4}
--------------

The MasterPure™ Complete DNA & RNA Purification Kit (epicenter, Madison, WI, USA) was used to isolate DNA from DBSs as recommended by the manufacturer. Briefly, six DBS punches were treated with proteinase K followed by adding a cell lysis solution and protein precipitation. Recovered DNA was re-suspended in 20--30 µl of TE buffer.

Targeted NGS PID Panel (T-NGS PID) {#S2-5}
----------------------------------

Ion AmpliSeq Designer software (Life Technologies, Carlsbad, CA, USA) was used for the design and synthesis of a multiplexed gene panel encompassing 265 PID genes. The list of PID genes screened for is provided in Table S1 in Supplementary Material. Primers were optimized to provide amplicons (200 bp) with at least 90% coverage of coding sequence and a minimum of 10 bp flanking regions of associated introns. Ten nanograms of extracted DNA samples were sufficient to generate the Ion Proton AmpliSeq library. Details of library preparation, NGS, data processing, bioinformatics analysis, workflow of detecting point mutations, and copy number variants (CNVs) were previously described ([@B28]). The assay has an overall sensitivity of 96% for single nucleotide variants (SNVs) and 92% for detecting Indels. CNV analyses have a sensitivity of 100% for detecting large homozygous deletions ([@B28]).

Sanger Sequencing {#S2-6}
-----------------

Identified mutations by T-NGS PID panel were confirmed by standard Sanger sequencing. Details of PCR, primers design, and sequencing was described previously ([@B32], [@B33]). Sequence data were aligned against the reference GenBank sequences and examined for variation. Novel mutations were compared against local Saudi Genomic as well as non-Saudi population databases. Pathogenicity of novel mutations was determined based on population allele frequency and *in silico* prediction tools.

Chr.22q11.2 Copy Number/Deletion Analysis {#S2-7}
-----------------------------------------

Copy number-based assays (RT-qPCR and single nucleotide polymorphism-microarrays) were used to detect this deletion. To test gDNA from NBS DBS samples with low TRECs, we used a TaqMan labeled *TBX1* real-time qPCR copy number assay (ThermoScientific).[^1^](#fn1){ref-type="fn"} This assay is run as a duplex real-time PCR of target gDNA (*TBX1*) as well the reference gene (*RNase P* H1 RNA gene) both of which are normally present as diploid copies. The comparative CT (ΔΔCT) method was then used to calculate the number of copies of the target sequence in each test sample \[measures the CT difference (ΔCT) between target and reference sequences, then compares the ΔCT values of test samples to a calibrator sample(s) known to have two copies of the target sequence\]. The copy number of the target is calculated to be two times the relative quantity.[^2^](#fn2){ref-type="fn"} Samples and controls (known 22q11.2 deletion and normal) were run in duplicates in each 96-well plate. Samples with abnormal copy number for *TBX1* (22q11.2 deletion) were repeated in duplicates as well. CopyCaller™ Software (ThermoFisher) was used to calculate target (*TBX1*) as well as reference (*RNAse P*) copy number in all samples.

Results {#S3}
=======

Neonatal Guthrie Card Samples {#S3-1}
-----------------------------

We used DBS punches from 8,718 previously collected, anonymized Guthrie cards. A cutoff of ≥36 TRECs/μL and Beta-actin copy of ≥56 copies/μL was determined as normal. Failed DBS samples were repeated. Samples with persistently low TRECs and normal Beta-actin copy number were subjected to 2nd tier testing (qPCR-based copy number analysis for 22q11.2 deletion) to rule out 22q11.2 deletion syndrome, and Proton-Ion Torrent (NGS)-based targeted primary immunodeficiency genes analysis. Experimental work flow is shown in Figure [1](#F1){ref-type="fig"}.

![Experimental workflow. Abbreviations: KFSHRC, King Faisal Specialist Hospital & Research Center; DBS, dried blood spot; TREC, T cell receptor excision circle; NGS, Next generation sequencing; PID, primary immunodeficiency disease; qPCR, quantitative polymerase chain reaction.](fimmu-09-00782-g001){#F1}

TREC Assay {#S3-2}
----------

8,333 of 8,718 tested samples had an initial TREC value above the cutoff. 315 samples had an initial TREC or Beta-actin copy value below the cutoff, which led us to perform a second (repeat) TREC analysis (retest-rate 3.6%). Most of these samples (299 of 315, 95%) passed the second tier with a TREC copy number above the cutoff. Therefore, only 16 of 8,718 (0.18% or 1/544) samples had persistently low TREC counts below the cutoff. These samples were suspected of having T-cell deficiency and were subjected to further investigations (recall rate 0.18%). A total of 70 samples with combined low TREC and beta-actin copy number failed both initial and repeat testing and were, therefore, excluded (failure rate 0.8%). Table S2 in Supplementary Material showed samples with duplicate low TREC copy number.

Mutations Detected by T-NGS PID Panel {#S3-3}
-------------------------------------

All 16 samples with low TREC assay underwent T-NGS PID panel. A homozygous mutation in *AK2*, a compound heterozygous mutation in *JAK3*, and a homozygous mutation in *MTHFD1* were identified in three samples, respectively, and confirmed by Sanger sequencing. Details of the mutations, gestational age, and TREC level are shown in Table [1](#T1){ref-type="table"}. The homozygous *AK2* mutation is a known Saudi mutation that has been previously reported to cause classical reticular dysgenesis ([@B34]). It is interesting to note that the recessive *JAK3* mutation was a compound heterozygous for a novel truncating and a rare deleterious mutation suggesting parental non-consanguinity. The *JAK3* and *MTHFD1* detected variants in samples 2 and 3 are novel.

###### 

Mutations detected by T-next generation sequencing (NGS) primary immunodeficiency disease panel.

  Sample                        T cell receptor excision circle copies/μL (initial/repeat)   Gene                            Mutation                        Protein effect   Zygosity                Mutation type                                  Detected by T-NGS   Confirmed by Sanger
  ----------------------------- ------------------------------------------------------------ ------------------------------- ------------------------------- ---------------- ----------------------- ---------------------------------------------- ------------------- ---------------------
  *SGP2017-00440*               6/0                                                          *AK2*                           NM_001625:exon6:c.524G \> C     p.R175P          Homozygous              SNV ([@B29])                                   YES                 YES
                                                                                                                                                                                                                                                                         
  *SGP2017-00442*               3/3                                                          *JAK3*                          NM_000215:exon10:c.1275T \> A   p.Y425X          Compound heterozygous   SNV[^a^](#tfn1){ref-type="table-fn"} (novel)   YES                 YES
  NM_000215:exon3:c.308G \> A   p.R103H                                                      (rare, 8.129e-6; deleterious)   YES                             YES                                                                                                         
                                                                                                                                                                                                                                                                         
  *SGP2017-00425*               34/36                                                        *MTHFD1*                        NM_005956:exon24:c.2404G \> A   p.V802I          Homozygous              SNV (rare, 7.326e-5; deleterious)              YES                 YES

*SNV, single nucleotide variant*.

*^a^Very rare deleterious SNVs (<http://gnomad.broadinstitute.org/>) which have never been reported as homozygous*.

Copy Number Variants {#S3-4}
--------------------

Copy number variation analyses were carried out for each of the low TREC samples to rule out large insertions or deletions. No large homozygous deletions were detected.

Chr.22q11.2 Copy Number/Deletion Analysis {#S3-5}
-----------------------------------------

Among the 16 samples with low TREC copy number, two samples with 22q11.2 deletion were suspected by qPCR. No further confirmatory testing was performed.

Prematurity {#S3-6}
-----------

692 out of the 8,718 samples were from preterm newborns (\<37 weeks gestation) representing 8% of all samples recruited. Three out of the sixteen samples with low TREC assay belonged to preterm newborn (19%).

SCID Incidence in Saudi Arabia {#S3-7}
------------------------------

Three suspected SCID cases were identified after screening 8,718 Saudi newborn Guthrie card samples based on EnLite™ Neonatal TREC assay followed by T-NGS PID Panel and confirmatory Sanger sequencing. These results indicate a frequency of SCID of 1/2,906 live births in Saudi Arabia. Further confirmatory testing using flow cytometry and clinical correlation were not possible per protocol.

Discussion {#S4}
==========

Severe combined immunodeficiency disease epidemiology from worldwide registries showed a geographical and racial variation. For multiple socio-cultural factors, consanguineous marriages are a common practice in the Middle East and Northern Africa (MENA) region with an overall incidence ranging between 20 and 50% ([@B27], [@B35]--[@B40]). This led to the abundance of autosomal recessive diseases among various MENA populations. Published data from highly consanguineous populations such as Kuwait showed an estimated incidence of 1/7,500 live birth for combined immunodeficiency diseases ([@B41]) and data from Saudi Arabia showed that SCID is the commonest PID (33%) ([@B21]). However, the true incidence of SCID among Saudi population was unknown. This study had provided the first population-based incidence of SCID at 1 in 2,906 Saudi live births, which is (20×) higher than the incidence reported from USA NBS programs ([@B19]). Although in this pilot study the sample size was relatively small to ascertain this high incidence, we believe that it is representative of the population of Saudi Arabia since our NBS services cover all regions of the country. A large scale NBS for SCID in Saudi Arabia will be needed to confirm this finding. This high incidence will increase the cost effectiveness ratio of implementing SCID NBS in such highly consanguineous population. This is possible provided that the health policy makers recognize the real incidence and the seriousness of such disease and provide all required resources to manage it.

Severe combined immunodeficiency disease is caused by mutations in one of several genes including *IL2RG, JAK3, DCLRE1C, RAG1, RAG2, IL7R, ADA, CD3D, CD3E, CD3Z, DOCK2, AK2*, and *TTC7A* ([@B23], [@B42], [@B43]). Additional genetic defects in *MTHFD1, RMRP, CORO1A, PNP, DOCK8, ATM*, and *BCL11B*, among others also cause combined immunodeficiencies, which can be detected by low TREC copy number analysis ([@B23]). TREC NBS has revealed a small number of infants with non-SCID T cell (idiopathic) lymphopenia for which no apparent cause was identified ([@B44]). Newly developed and commercially available SCID NGS gene panels are available for clinicians to order on newborns with low TREC assay. However, such panels will miss many of the possible causing syndromes in addition to non-SCID causing defects. Whole-exome sequencing (without concomitant copy number analysis) will miss diagnoses such as 22q11.2 deletion syndrome, trisomy 21, deletions, and other cytogenetic syndromes. Therefore, it is important to have a short list of all possible syndromes and genetic defects that will prompt further follow-up investigations.

Dried blood spots are potential resources for genetic and genomic analysis. Recent studies showed that sufficient DBS DNA can be extracted and used for NGS to perform whole exome sequencing (WES) and whole genome sequencing (WGS) without genome amplification ([@B45]). The use of next-generation sequencing has the potential to be integrated in SCID NBS programs to facilitate and accelerate genetic testing and final diagnosis of affected newborns. However, appropriate utilization of these technologies will require the capacity to manage and interpret large amounts of genetic data. Implementing such testing will also raise several questions about the ability of clinicians to interpret and effectively communicate the generated genetic data ([@B46], [@B47]). A more focused, clinically driven NGS gene panel-based analysis covering entire genes (to capture known and novel variants) will be more appropriate for initial screening for mutations that can explain the low TREC counts and will reduce many of the complexities associated with WES or WGS. Targeted NGS gene panel assay has a rapid turn-around time and the lists of potential candidate variants generated is much shorter compared to WES or WGS. This is expected to facilitate result interpretation and reduce the risk of incidental findings. WES or WGS can be applied to unsolved cases for new gene discovery. All novel variants, even in known PID genes will require functional and experimental validation to prove that they are actually deleterious and will remain the benchmark for causal association with a disease phenotype.

Most newborns found to have low TREC counts will undergo extensive follow-up genetic testing to identify the possible underlying immune defect. This approach has revealed a broad range of conditions with a wide spectrum of clinical severity in which immune deficiency may occur, some of which were not previously appreciated to cause a significant immunodeficiency phenotype. Currently, the post-NBS genetic testing for SCID related molecular defects is initiated after performing full clinical and immunological assessments. However, the development of high-throughput DNA sequencing technologies has revolutionized the genetic testing approach potentially allowing early initiation of genetic testing, even before starting immunological work up, which may lead to a more efficient and rapid identification of the genetic basis of inherited inborn errors of immunity. An ideal NBS NGS PID gene panel will include all PID genes known to be associated with low TREC counts. This list can be easily revised on a regular basis to include newly discovered genes. Therefore, we believe that this combined approach (TREC followed by NGS-based PID gene analysis) can be used efficiently in the screening and diagnosis of newborns with low TREC counts.

In this study, we elected to use a high TREC copies cutoffs (36 copies/μL) since we had no access to patients to perform further immunological testing. In the USA and Europe, lower cutoffs had been implemented in routine NBS ([@B48]). Table [2](#T2){ref-type="table"} demonstrates the performance of this assay in Saudi newborns based on various TREC copies cutoffs scenarios. At 36 copies/μL and based on a population of 570,000 newborns, an estimated 1,026 newborns will need referral for clinical and immunological evaluations and hence a high number of newborns will be called for retesting creating unnecessary anxiety among parents and increase in health-care expenditures. A lower cutoff, at 20 copies/μL, is expected to identify all classical SCID cases and result in a more reasonable number of clinical referrals (171). However, an atypical SCID and other T cell lymphopenia can be missed. Case in point, the sample with MTHFD1 deficiency would not have been identified at this low cutoff (Table [1](#T1){ref-type="table"}). MTHFD1 deficiency is a recently discovered metabolic disorder characterized by severe combined immunodeficiency, megaloblastic anemia, and neurological deficits ([@B49], [@B50]). A larger, more comprehensive pilot study supported by clinical outcomes of various cutoff limits should determine the final TREC cutoff level to be used in routine NBS that will ensure the identification of all babies with typical SCID.

###### 

Comparison of number of needed referrals for confirmatory studies for severe combined immunodeficiency disease based on T cell receptor excision circle (TREC) concentration cutoffs.

                                                                     35 copies/μL   30 copies/μL   25 copies/μL   20 copies/μL   15 copies/μL
  ------------------------------------------------------------------ -------------- -------------- -------------- -------------- --------------
  Number and (%) positives after first TREC assay                    315 (3.6%)     263 (3%)       199 (2.3)      161 (1.8)      124 (1.4)
  Number and (%) presumptive positives (after repeated TREC assay)   16 (0.18)      12 (0.14)      8 (0.09)       3 (0.03)       3 (0.03)
  Total number of referrals per annum (KSA)^a^                       1,026          798            513            171            171
  Total number of referrals per annum (UK) (14)^b^                   1,680          554            420            210            NA
  Total number of referrals per annum (Netherlands) (18)^c^          1,209          946            403            140            NA

*Numbers were calculated based on a total of 570,000^a^, 700,000^b^, and 178,000^c^ annual live births in KSA, UK, and Netherlands respectively*.

*NA, not available*.

The economical evaluation of the cost effectiveness of novel technologies for neonatal screening is a challenging task, as various factors determine their outcome. Extensive genetic testing is already part of the routine work up of symptomatic newborns. It is now clear that the targeted NGS approach is a cost-effective and more rapid alternative to Sanger sequencing especially for the evaluation of large genes and multi-genetic disorders (e.g., Omenn syndrome) ([@B28]). The consumables cost for our targeted NGS method is approximately \$250 per sample based upon multiplexing of approximately 40 samples per run. A comprehensive cost effectiveness study of implementing additional NGS-based testing will be needed before making it part of the TREC-based NBS program.

In summary, this TREC-based SCID NBS pilot study provides the first evidence of high incidence of SCID among the Saudi population and demonstrates the feasibility of using T-NGS PID panel from Guthrie card DBSs as a new reliable, rapid, and cost-effective mutation screening method for newborns with low TREC counts.
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